tetano
Editor, Senior Moderator
Vaccine
Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial ☆
David W. Scheifelea, Corresponding author contact information, E-mail the corresponding author, E-mail the corresponding author,
Brian J. Wardb,
Marc Dionnec,
Otto G. Vanderkooid,
Mark Loebe,
Brenda L. Colemanf,
Yan Lig,
PHAC/CIHR Influenza Research Network (PCIRN)h
a Vaccine Evaluation Center, University of British Columbia, Vancouver, BC, Canada
b Vaccine Study Center, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
c Institut National de Sant? Publique du Qu?bec, Qu?bec City, Quebec, Canada
d University of Calgary, Alberta Health Services and Alberta Children's Hospital, Calgary, Alberta, Canada
e McMaster University, Hamilton, Ontario, Canada
f Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
g Virology Section, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
h Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN), Dalhousie University, Halifax, Nova Scotia, Canada
Received 23 August 2011. Revised 25 April 2012. Accepted 15 May 2012. Available online 28 May 2012.
http://dx.doi.org/10.1016/j.vaccine.2012.05.029, How to Cite or Link Using DOI
When Canada chose a novel adjuvanted vaccine to combat the 2009 influenza pandemic, seasonal trivalent inactivated vaccine (TIV) was also available but compatibility of the two had not been assessed. To compare responses after concurrent or sequential administration of these vaccines, adults 20?59 years old were randomly assigned (1:1) to receive ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix?, GSK, Quebec City, Quebec), with TIV (Vaxigrip?, Sanofi Pasteur, Toronto) given concurrently or 21 days later. Blood was obtained at baseline and 21 days after each vaccination to measure hemagglutination inhibition (HAI) titers. Adverse effects were assessed using symptom diaries and personal interviews. 282 participants completed the study (concurrent vaccines 145, sequential vaccines 137). HAI titers to H1N1pdm09 were ≥40 at baseline in 15?18% of participants and following vaccination in 91?92%. Initially seropositive subjects (titer ≥10) had lower H1N1pdm09 geometric mean HAI titers (GMT) after concurrent than separate vaccinations (320.0 vs 476.5, p = 0.039) but both exceeded GM responses of initially na?ve participants, which were unaffected by concurrent TIV. Responses to TIV were not lower after concurrent than separate vaccination. Adverse event rates were not increased by concurrent vaccinations above those with H1N1pdm09 vaccine alone. This adjuvanted H1N1pdm09 vaccine was immunogenic and compatible with concurrently administered TIV.
Highlights
► An evaluation of Canadian-made AS03-adjuvanted H1N1pdm09 vaccine in adults. ► Evaluation included compatibility with trivalent inactivated influenza (TIV) vaccine. ► One dose of H1N1pdm09 vaccine (3.75 μg) was sufficiently immunogenic. ► Concurrent dosing did not adversely affect immune responses to either vaccine. ► Concurrent vaccinations did not increase rates of systemic symptoms.
http://www.sciencedirect.com/science/article/pii/S0264410X12007335
Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial ☆
David W. Scheifelea, Corresponding author contact information, E-mail the corresponding author, E-mail the corresponding author,
Brian J. Wardb,
Marc Dionnec,
Otto G. Vanderkooid,
Mark Loebe,
Brenda L. Colemanf,
Yan Lig,
PHAC/CIHR Influenza Research Network (PCIRN)h
a Vaccine Evaluation Center, University of British Columbia, Vancouver, BC, Canada
b Vaccine Study Center, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
c Institut National de Sant? Publique du Qu?bec, Qu?bec City, Quebec, Canada
d University of Calgary, Alberta Health Services and Alberta Children's Hospital, Calgary, Alberta, Canada
e McMaster University, Hamilton, Ontario, Canada
f Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
g Virology Section, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
h Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN), Dalhousie University, Halifax, Nova Scotia, Canada
Received 23 August 2011. Revised 25 April 2012. Accepted 15 May 2012. Available online 28 May 2012.
http://dx.doi.org/10.1016/j.vaccine.2012.05.029, How to Cite or Link Using DOI
When Canada chose a novel adjuvanted vaccine to combat the 2009 influenza pandemic, seasonal trivalent inactivated vaccine (TIV) was also available but compatibility of the two had not been assessed. To compare responses after concurrent or sequential administration of these vaccines, adults 20?59 years old were randomly assigned (1:1) to receive ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix?, GSK, Quebec City, Quebec), with TIV (Vaxigrip?, Sanofi Pasteur, Toronto) given concurrently or 21 days later. Blood was obtained at baseline and 21 days after each vaccination to measure hemagglutination inhibition (HAI) titers. Adverse effects were assessed using symptom diaries and personal interviews. 282 participants completed the study (concurrent vaccines 145, sequential vaccines 137). HAI titers to H1N1pdm09 were ≥40 at baseline in 15?18% of participants and following vaccination in 91?92%. Initially seropositive subjects (titer ≥10) had lower H1N1pdm09 geometric mean HAI titers (GMT) after concurrent than separate vaccinations (320.0 vs 476.5, p = 0.039) but both exceeded GM responses of initially na?ve participants, which were unaffected by concurrent TIV. Responses to TIV were not lower after concurrent than separate vaccination. Adverse event rates were not increased by concurrent vaccinations above those with H1N1pdm09 vaccine alone. This adjuvanted H1N1pdm09 vaccine was immunogenic and compatible with concurrently administered TIV.
Highlights
► An evaluation of Canadian-made AS03-adjuvanted H1N1pdm09 vaccine in adults. ► Evaluation included compatibility with trivalent inactivated influenza (TIV) vaccine. ► One dose of H1N1pdm09 vaccine (3.75 μg) was sufficiently immunogenic. ► Concurrent dosing did not adversely affect immune responses to either vaccine. ► Concurrent vaccinations did not increase rates of systemic symptoms.
http://www.sciencedirect.com/science/article/pii/S0264410X12007335